Toggle navigation
Home
Search
Services
Blog
Contact
About
Clinical Evaluation of Biological Modifiers
Berd, David
Fox Chase Cancer Center, Philadelphia, PA, United States
Search 18 grants from David Berd
Search grants from Fox Chase Cancer Center
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Native Americans and Research Careers
Vascular AT1 Receptor Role in Blood Pressure Control
Innovative Software to Boost Reading Skills
Alanine Transfer RNA Recognition by A Mutant Synthetase
Germiline Transformation of the Drosophila Egf Receptor
Recently added grants:
Structure, function and aggregation of lens ?-crystallins by CryoEM
Lens epithelial cell heterogeneity during development
Molecular, cellular, anatomical and neurobiological investigation of melanopsin-expressing corneal innervation, and its role in pain and photophobia
Mechanism and Uses of Transmembrane Helix Insertion by Soluble Peptides
New Molecular Probes For Protein Kinases
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM007432-001007
Application #
3608443
Study Section
Project Start
1983-09-30
Project End
Budget Start
1986-04-01
Budget End
1986-07-31
Support Year
Fiscal Year
1986
Total Cost
Indirect Cost
Institution
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Related projects
NIH 1986
N01 CM
Clinical Evaluation of Biological Modifiers
Berd, David / Fox Chase Cancer Center
NIH 1985
N01 CM
Clinical Evaluation of Biological Modifiers
Berd, David / Fox Chase Cancer Center
Publications
Berd, D; Mastrangelo, M J
(1987)
Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibody.
Cancer Res 47:2727-32
Comments
Be the first to comment on this grant